

Longevity – Innovation for a healthy tomorrow


Medical advances are not only changing the way we age, but also increasing our life expectancy. However, the aim is not only to live longer, but also, ideally, to live healthier lives. This trend, known as “longevity,” has gained momentum and could also bring exciting opportunities for investors.



Longevity – Innovation for a healthy tomorrow

Demographic change and medical advancement have significantly increased life expectancy worldwide. But it's not just about living longer, it's also about aging healthier. This is precisely where the megatrend of “longevity” comes in, which aims not only to extend health and life expectancy, but also to open up new economic opportunities.

Share of people over 65 in the global population, in percent



Source: World Bank Group

Longevity encompasses a wide range of innovations in medicine, technology, and lifestyle that aim to enable longer and healthier lives. Sectors such as digital healthcare, genomics, medical imaging, medical devices, and preventive and personalized healthcare solutions are particularly affected.

Digital healthcare

Companies are developing AI-powered applications, virtual care platforms, and data-driven clinical tools that facilitate access to healthcare and increase efficiency. These technologies enable early detection of diseases such as dementia and improve decision-making in healthcare. According to forecasts, the market for AI in healthcare will grow to over USD 110 billion by 2030, underscoring the enormous potential of this sector.

Genomics

Advances in gene editing and cellular reprogramming are opening up new possibilities in medicine. By analyzing and utilizing genetic data, diseases can be detected earlier and individualized therapies developed. The goal is to correct biological dysfunctions and enable regenerative treatments. Strong market growth is also expected here, with an annual growth rate of over 12 percent until 2030.

Medical imaging and devices

Modern imaging systems and diagnostic technologies play a crucial role in the early detection and treatment of age-related diseases. At the same time, wearable and connected medical devices are gaining importance as they enable continuous monitoring and preventive care. The market for medical devices could reach a volume of over USD 700 billion by 2030.

Preventive and personalized health solutions

Prevention is becoming increasingly important in order to extend the healthspan. Companies that offer personalized wellness programs, nutritional products, dietary supplements, and behavioral health solutions are helping to prevent chronic diseases and improve quality of life. According to the US National Institute of Health, by 2035 a large proportion of the population over 50 will have at least one chronic disease, increasing the need for such solutions.

Lifestyle and everyday support

In addition to medical advances, support in everyday life also plays a central role. Companies that develop technologies and services for older people, such as smart household appliances, barrier-free living solutions, or platforms for social interaction, are benefiting from growing demand. The fitness and wellness sector is also experiencing an upswing due to the desire for healthy aging. Wearables that monitor health data in real time or apps that motivate people to exercise more and eat healthier are just a few examples of innovations that can improve quality of life in old age.

Longevity as an investment opportunity

The economic impact of the longevity trend is enormous. The so-called “longevity economy” encompasses all industries that benefit from an aging population and its specific needs. Companies that develop innovative solutions for prevention, diagnostics, treatment, and everyday support have significant growth potential.

For investors who want to take advantage of this megatrend, the Open-End Tracker Certificate on the Solactive Longevity Innovators Index offers an opportunity to invest specifically in companies that specialize in technologies and services that promote longevity and healthy aging. The index comprises up to 25 companies from the five key longevity categories. The companies are selected based on a data-driven algorithm that analyzes publicly available information. The composition is reviewed and adjusted every six months to ensure that the index always reflects the most innovative and promising companies.

Conclusion

Longevity is more than just demographic change—it is a global megatrend that is fundamentally changing the way we live and age. The combination of medical advances, technological innovations, and growing awareness of healthy living offers new opportunities not only for society but also for investors. Investing in longevity companies can offer attractive long-term growth opportunities, but requires careful consideration of the associated risks.

Product Details: Tracker Certificates on the Solactive Longevity Innovators Index

Underlying	Solactive Longevity Innovators Index	
Initial Fixing	02 February 2026	
Maturity	Open End	
Management Fee	1.00 % p.a.	
Reference Currency of underlying	USD	
End of subscription	30 January 2026, 4:00 PM	
Tranche	CHF-Version	USD-Version
ISIN	CH1483499211	CH1483499443
Swiss Secu- rity Number /	148349921 /	148349944 /
Symbol	ZSTADV	ZSOBCV
Issue Price	CHF 100 incl. CHF 1.50 fee	USD 100 incl. USD 1.50 fee

Issuer: Bank Vontobel AG, Zurich (Moody's long-term deposit rating: Aa3). SSPA designation: Tracker certificate (1300). Index provider: Solactive. Listing: SIX Swiss Exchange. The final terms and conditions with legally binding information and documents such as the key information document and the prospectus, as well as further information, are available at any time at markets.vontobel.com. Investors bear the default risk of the issuer.

Investment Suitability

This publication is not part of an offer or a recommendation and does not take into account your knowledge, experience and personal circumstances, which are necessary for personal investment advice.

Legal information**Legal Notices:**

This publication is deemed to be marketing material within the meaning of Article 68 of the Swiss Financial Services Act (FINSA) and for informational purposes only, does not represent an investment recommendation or advice and contains neither an offer nor an invitation to make an offer. It does not replace the qualified advice necessary before any purchase decision, in particular as regards all associated risks. We will be happy to provide you with the legal binding documents such as the key information sheet or the prospectus as well as the information brochure "Risk Involved in Trading Financial Instruments" at any time and free of charge. Before purchasing derivative products, investors should read the relevant product documentation. This information contains an indication of past performance. Past performance is not a reliable indicator of future results. This information contains information on future performance. Such forecasts are not a reliable indicator of future performance. This publication was prepared by the Structured Products unit of our institution and is not the result of financial analysis. Solactive AG ("Solactive") is the licensor of the Solactive Longevity Innovator Index (the "Index"). The financial instruments that are based on the Index are not sponsored, endorsed, promoted or sold by Solactive in any way and Solactive makes no express or im-plied representation, guarantee or assurance with regard to: (a) the advisability in investing in the financial instruments; (b) the quality, accuracy and/or complete-ness of the Index; and/or (c) the results obtained or to be obtained by any person or entity from the use of the Index. Solactive reserves the right to change the methods of calculation or publication with respect to the Index. Solactive shall not be liable for any damage suffered or incurred as a result of the use (or inability to use) of the Index. Structured products are not regarded as collective investment schemes within the meaning of the Federal Act on Collective Investment Schemes (CISA) [status as of 1 July 2016] and are therefore not subject to the approval or supervision of the Swiss Financial Market Supervisory Authority FINMA. The value of structured products may depend not only on the performance of the underlying, but also on the creditworthiness of the issuer. The investor is exposed to the risk of the issuer / guarantor defaulting. This publication may not be reproduced in whole or in part without the written permission of Vontobel. This publication and the financial products outlined therein are not intended for persons subject to jurisdiction, which limits or prohibits the sale of financial products or the dissemination of this publication and/or the information contained therein.

This publication corresponds to marketing material in accordance with Art. 68 of the Swiss FinSA and is for information purposes only. We are happy to provide you with the legally binding documents for the financial products mentioned, such as the basic information sheet or the prospectus, as well as the information brochure "Risks in trading financial instruments", free of charge and at any time.

Nothing contained in this publication should be construed as a solicitation or an offer or a recommendation to use any service or product, to buy or sell any investment or to carry out any other transaction. The information contained in this publication does not constitute investment advice or financial analysis. It is for information purposes only and therefore does not meet statutory requirements in terms of ensuring the impartiality of financial analysis. The information and views contained in this publication are intended for information and marketing purposes only and do not take into account any individual investment objectives, financial circumstances or requirements. The products and services described in this publication are supplied exclusively under the agreement entered into with the investor. Bank Vontobel AG makes no warranty as to the reliability or completeness of the information contained in this publication and disclaims all liability for any loss that may be suffered as a result of using such information. The nature, scope and prices of the products and services described in this publication may vary from one country to another and may change without notice at any time. Certain services and products are not available worldwide or from all companies within Vontobel. In addition, they may be subject to legal restrictions in certain countries. Information on asset and currency allocations is approximate, intended for general guidance only and subject to change at any time. Such allocations may also vary from one client portfolio to another. Prior to making any investment decision or making any decision to use any products or services described in this publication, investors should determine whether such products and services are appropriate for their individual needs and independently verify (by consulting professional advisors where necessary) the specific risks involved (risk of loss, currency risks) and the potential regulatory, credit, tax and accounting implications. The tax treatment of products and services described in this publication will depend on individual circumstances and may change in the future. Bank Vontobel AG makes no warranty that any investment decisions and/or investments made in relation to products or services described in this publication will take due account of the investor's tax situation and accepts no liability in respect of the tax treatment of assets or any income generated therefrom. Moreover, Bank Vontobel AG makes no recommendation or endorsement with regard to any products or services described in this publication or their suitability for specific investors. Neither does it make any representation or warranty of any kind as to future performance. Investors should be aware that there are certain risks associated with all types of investment and that investments may be subject to sudden and large falls in their value. Investors are hereby advised to take note of the risks involved, which may be substantial. The products and services described herein are only intended for investors who understand and are willing to accept the associated risks. If the securities market becomes illiquid, it may not be possible to realize the value of certain investment products immediately. If investments are liquidated, investors may get back less than the amount originally invested. Investments in foreign currencies are subject to exchange rate fluctuations. Investing in emerging markets involves special or higher levels of risk. For this reason, it may be difficult to quantify the value of an investment and the risks to which investors are exposed. The mention of specific companies is for illustrative purposes only and does not constitute a recommendation to buy, sell, or hold their securities.

Structured products are not considered collective investment schemes within the meaning of the Federal Act on Collective Investment Schemes (CISA) [as of July 1, 2016] and are therefore not subject to authorization and supervision by the Swiss Financial Market Supervisory Authority FINMA. Investments in structured products are subject to the default risk of the respective issuer and other specific risks. Before purchasing derivative products, investors should read the relevant product documentation, such as the Index Guide, Final Terms, together with the Vontobel Swiss Base Prospectus for the Issue of Securities available on the website <https://markets.vontobel.com>. The scenarios presented in this publication do not provide any indication of the actual performance of the underlying asset and serve only as illustrative examples and are not the result of a financial analysis. This information contains data relating to future performance. Such forecasts are not a reliable indicator of future performance.

This publication may not be reproduced in whole or in part without the written permission of Vontobel. This publication and the financial products described herein are not intended for persons who are subject to a jurisdiction that restricts or prohibits the distribution of financial products or the dissemination of this publication or the information contained therein. If you have any questions about our products, please do not hesitate to contact us. All information is provided without guarantee. All information on products from parties outside of Bank Vontobel AG are available with the respective providers of the products.

All information is provided without guarantee. All information on products from parties outside Bank Vontobel AG is available from the respective product providers.

Bank Vontobel AG
 Gotthardstrasse 43
 8022 Zurich
 Switzerland

vontobel.com